title: T-regulatory cell modulation: the future of cancer immunotherapy?
abstract: T-regulatory cells suppress anti-tumour immunity in cancer patients and in murine tumour models. Furthermore, their activity is likely to have an effect on the effectiveness of immunotherapeutic treatments for cancer. Here we describe the current status of developing clinical strategies for modulating Treg activity in cancer patients.
authors.affiliation: Department of Cellular and Molecular Medicine, St George's University of London, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Nizar
authors.forename: J
authors.initials: J
authors.lastname: Copier
authors.forename: B
authors.initials: B
authors.lastname: Meyer
authors.forename: M
authors.initials: M
authors.lastname: Bodman-Smith
authors.forename: C
authors.initials: C
authors.lastname: Galustian
authors.forename: D
authors.initials: D
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Dalgleish
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D000970:Antineoplastic Agents